-
effectivehealthcare-admin.ahrq.gov/sites/default/files/assessing-applicability.ppt
January 01, 2009 - Assessing Applicability
Assessing Applicability
Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Methods Guide for Effectiveness and Comparative Effectiveness Reviews
Assessing Applicability
Systematic Review Process Overview
*
Systematic Review Process Overview
This slide illustrates th…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cesarean-birth-future_research.pdf
August 09, 2012 - where the ‘immediately available’ standard fits in that definition or
if it even is an appropriate factor … the ‘immediately available’ standard fits in that definition or
19
if it even is an appropriate factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/medicine-safety-call-center_research.pdf
September 01, 2007 - 2000) report that independent collection of reports and analysis
by peer evaluation is an important factor … As such, financial incentives can serve an additional factor in
promoting the adoption of a community-pharmacy … Success Factor Implementation Possible IT Solutions
Immunity Anonymity of reporters,
participants … Services for
heterogeneous data and
IT Architecture for Post-Marketing Surveillance
22
Success Factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/it-architecture-for-post-marketing-surveillance-arizona-cert.pdf
September 01, 2007 - 2000) report that independent collection of reports and analysis
by peer evaluation is an important factor … As such, financial incentives can serve an additional factor in
promoting the adoption of a community-pharmacy … Success Factor Implementation Possible IT Solutions
Immunity Anonymity of reporters,
participants … Services for
heterogeneous data and
IT Architecture for Post-Marketing Surveillance
22
Success Factor
-
effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/what-is-the-comparative-effectiveness-of-conventional-ct-mdct-including-virtual-ct-bronchoscopy-petpet-ct-and-mri-for-the-diagnosis-or-pretreatment-staging-of-small-cell-and-non-small-cell-lung-cancer
November 01, 2017 - socioeconmically disadvantaged populations are especially at risk due to high rates of smoking, a strong risk factor
-
effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/comparative-effectiveness-of-conventional-computed-tomography-ct-multidetector-computed-tomography-mdct-ct-colonography-fludeoxyglucose-positron-emission-tomography-fdg-pet-or-fdg-petct-magnetic-resonance-imaging-mri-ultraso
November 01, 2017 - Mesorectal involvement in the circumferential margin (CRM) is an important factor in deciding the need
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/back-pain-imaging_clinician.pdf
April 01, 2016 - Early Imaging for Back Pain and
Clinical Outcomes in Older Adults: A
Brief Summary of Findings and Key
Points for Clinician-Patient Discussions
KEY CLINICAL ISSUE
What were the clinical outcomes and use of health care resources among older
adults who received early imaging when compared with those who did not re…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/medical-test-reviews-genetic.ppt
June 01, 2012 - Penetrance is a key factor in determining the future risk of developing disease and assessing the overall … The first factor is whether the test is for an inherited versus an acquired mutation or variation, and … Assessment of human epidermal growth factor receptor 2 (HER2) status is used to manage patients with … It is the key preanalytic factor with influence on analytic validity. … This key preanalytic factor has an important influence on analytic validity and was used in the analytic
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/medical-test-reviews-genetic.ppt
June 01, 2012 - Penetrance is a key factor in determining the future risk of developing disease and assessing the overall … The first factor is whether the test is for an inherited versus an acquired mutation or variation, and … Assessment of human epidermal growth factor receptor 2 (HER2) status is used to manage patients with … It is the key preanalytic factor with influence on analytic validity. … This key preanalytic factor has an important influence on analytic validity and was used in the analytic
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/procalcitonin_research-protocol.pdf
September 08, 2011 - would be a trial in which randomized assignment to treatment groups
would be stratified by predictive factor … level or patients were randomized to
receive treatment guided by predictive factor or not. … adequately powered
stratified randomization would allow valid inferences of treatment by
predictive factor … of two treatments, whereas single-arm studies can only assess the
association between predictive factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/s81.pdf
October 01, 2007 - Female sex is an independent risk factor for bleeding on
anticoagulation.24 Codes for complications and … The model would overestimate the true ADE rate by
a factor of 8, but the crude rate of predicted ADEs … A very low PPV would
require a high discount factor of nearly 97% to estimate the
rate of drug-induced … This high discount factor and
the lack of clinically specific markers for delirium decrease
the likelihood
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/tech-brief-37-opiod-use-adults-comments.pdf
November 03, 2020 - Yes, we (and the included multivariable
analyses) treat each risk factor as
independent. … Regarding tobacco use, the risk factor is not
starting tobacco use, but instead current
tobacco use … There are only a
handful, and this is the limiting factor.
Thank you
Peer Reviewer 1 e. … Each factor is set
out in turn and gaps are adequately described. … AHRQ’s list of risk factors for overdose and death
ignores this important factor.
-
effectivehealthcare-admin.ahrq.gov/products/diabetes-medicare-use/research
December 01, 2019 - It is a major risk factor for cardiovascular disease and the leading cause of kidney failure, nontraumatic
-
effectivehealthcare-admin.ahrq.gov/products/thromboembolism-update/research-2017
January 01, 2021 - LMWH and factor Xa inhibitor (FXaI) comparisons are inconsistent across VTE outcomes, but LMWH has less
-
effectivehealthcare-admin.ahrq.gov/products/horizon-scan/research
July 01, 2019 - was due to the absence of public information on this intervention until attainment of FDA approval—a factor
-
effectivehealthcare-admin.ahrq.gov/products/worker-health/research-protocol
December 01, 2019 - Skip to main content
An official website of the Department of Health & Human Services
Careers
Contact Us
Español
FAQs
Effective Health Care Program
Powered by the Evidence-based Practice Centers
…
-
effectivehealthcare-admin.ahrq.gov/products/worker-safety-wellness/protocol
December 01, 2024 - Skip to main content
An official website of the Department of Health & Human Services
Careers
Contact Us
Español
FAQs
Effective Health Care Program
Powered by the Evidence-based Practice Centers
…
-
effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/with-the-rates-of-birth-by-cesarean-section-on-the-rise-what-factors-influence-and-which-have-the-greatest-impact-on-the-probability-of-delivery-by-cesarean-in-low-risk-women-which-interventions-are-most-effective-at-reducin
November 01, 2017 - Skip to main content
An official website of the Department of Health & Human Services
Careers
Contact Us
Español
FAQs
Effective Health Care Program
Powered by the Evidence-based Practice Centers
…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-264-maternal-morbidity-mortality-disposition-comments.pdf
December 21, 2023 - • The importance and role of data in risk factor research was raised primarily by one peer
reviewer … Given the
difficulty of writing specific
search algorithms to identify
risk factor research, we
determined
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/crohns-disease-future_research.pdf
July 01, 2016 - although use of these medications was not
routine until the 1990s.4 The first biologic tumor necrosis factor … Stelara)†
0 1
TNF = tumor necrosis factor.
† Stakeholder provided comparison. … 0
Other: TNF-alpha inhibitor versus new treatment (that is
safer)†
0 1
TNF = tumor necrosis factor … Stelara)†
0 1
TNF: Tumor necrosis factor.
† Stakeholder provided comparison. … 0
Other: TNF-alpha inhibitor versus new treatment (that is
safer)†
0 1
TNF = tumor necrosis factor